Alkermes 对比 ANI Pharmaceuticals
可添加、更换或移除公司，最多四家。
简而言之
- Alkermes 规模更大:2025 财年营收 $1.5B，ANI Pharmaceuticals 为 $883M，约为后者的 1.7 倍。
- ANI Pharmaceuticals 营收增长更快(43.8%，对方为 −5.3%)。
- Alkermes 每一美元销售额中留下的营业利润更多(营业利润率 17.2%，对方为 12.6%)。
- Alkermes 将更多销售额转化为自由现金流(自由现金流利润率 32.6%，对方为 19.4%)。
- 投资者愿为 Alkermes 每一美元的盈利支付更高价格：市盈率 114.8x，而 ANI Pharmaceuticals 为 15.7x。
| 最近财年 | ALKS · FY25 | ANIP · FY25 |
|---|---|---|
| 规模 | ||
| 市值 | $7.6B | $1.6B |
| 营收 | $1.5B | $883M |
| 自由现金流 | $480M | $171M |
| 净利润 | $242M | $78.3M |
| 增长 | ||
| 营收增长 | −5.3% | 43.8% |
| 5年增长率 | 7.3% | 33.5% |
| 股数变化 | −0.3% | 9.9% |
| 盈利能力 | ||
| 毛利率 | 86.7% | — |
| 营业利润率 | 17.2% | 12.6% |
| 净利率 | 16.4% | 8.9% |
| 自由现金流利润率 | 32.6% | 19.4% |
| 资本回报率 | — | 15.9% |
| 股本回报率 | 14.7% | 16.6% |
| 资产负债表 | ||
| 净债务 | — | $23.7M |
| 净债务 / EBITDA | — | 0.1x |
| 股息与回购 | $0.0M | $13.4M |
| 估值与质量 | ||
| 市盈率 | 114.8x | 15.7x |
| Piotroski F 分数 | — | 6 |
FY16
ALKS $746M
ANIP $129M
FY17
ALKS $903M
ANIP $177M
FY18
ALKS $1.1B
ANIP $202M
FY19
ALKS $1.2B
ANIP $207M
FY20
ALKS $1.0B
ANIP $209M
FY21
ALKS $1.2B
ANIP $216M
FY22
ALKS $1.1B
ANIP $316M
FY23
ALKS $1.7B
ANIP $487M
FY24
ALKS $1.6B
ANIP $614M
FY25
ALKS $1.5B
ANIP $883M
ALKS
ANIP
FY16
ALKS −28.0%
ANIP 15.6%
FY17
ALKS −16.4%
ANIP 16.0%
FY18
ALKS −9.1%
ANIP 17.5%
FY19
ALKS −15.0%
ANIP 7.9%
FY20
ALKS −10.8%
ANIP −7.7%
FY21
ALKS 8.3%
ANIP −18.4%
FY22
ALKS −0.6%
ANIP −11.2%
FY23
ALKS 24.9%
ANIP 9.7%
FY24
ALKS 27.0%
ANIP 0.1%
FY25
ALKS 17.2%
ANIP 12.6%
ALKS
ANIP
FY16
ALKS −$107M
ANIP $22.9M
FY17
ALKS −$32.1M
ANIP $29.1M
FY18
ALKS $29.9M
ANIP $61.3M
FY19
ALKS −$18.9M
ANIP $39.0M
FY20
ALKS $40.6M
ANIP $9.1M
FY21
ALKS $73.7M
ANIP $0.8M
FY22
ALKS −$17.2M
ANIP −$40.1M
FY23
ALKS $353M
ANIP $110M
FY24
ALKS $406M
ANIP $47.8M
FY25
ALKS $480M
ANIP $171M
ALKS
ANIP
FY16
ALKS −15.5%
ANIP 5.3%
FY17
ALKS −11.4%
ANIP 5.3%
FY18
ALKS −8.0%
ANIP 11.0%
FY19
ALKS −15.9%
ANIP 5.8%
FY20
ALKS −11.6%
ANIP −3.6%
FY21
ALKS 10.8%
ANIP −7.0%
FY22
ALKS −0.6%
ANIP −5.2%
FY23
ALKS 57.2%
ANIP 8.5%
FY24
ALKS —
ANIP 0.1%
FY25
ALKS —
ANIP 15.9%
ALKS
ANIP
各公司最近一个财年的数据；各公司财年结束月份不同。在越高(或越低)明显越好的行中，突出显示最佳值。不构成投资建议。